Pancrelipase

CHEMBL2108074 Phase 4 Disetujui Enzyme
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A combination of digestive enzymes (lipase, amylase, and protease) derived from porcine pancreas, used to treat exocrine pancreatic insufficiency in patients with cystic fibrosis, chronic pancreatitis, or following pancreatic surgery. Taken with meals, it replaces enzymes the pancreas cannot produce and improves nutrient absorption.

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A combination of digestive enzymes (lipase, amylase, and protease) derived from porcine pancreas, used to treat exocrine pancreatic insufficiency in patients with cystic fibrosis, chronic pancreatitis, or following pancreatic surgery. Taken with meals, it replaces enzymes the pancreas cannot produce and improves nutrient absorption.

Yes, Pancrelipase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108074. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.